Clinical Associate Professor
Medical Director CVPath Institute Inc.
110 South Paca St., 7th floor
Education and Training
1994 B.A. (Political Science), Cum Laude, Kenyon College
2000 M.D. Vanderbilt University School of Medicine
Post Graduate Education and Training:
07/00-06/01 Intern in Medicine, Internal Medicine, Massachusetts General Hospital, Boston, MA, Hasan Bazari MD, PhD
07/01-06/02 Resident in Medicine, Internal Medicine, Massachusetts General Hospital, Boston, MA, Hasan Bazari MD, PhD
07/02-06/04 Clinical Fellow in Cardiology, Cardiology, Massachusetts General Hospital, Boston, MA, Peter Yurchak, MD
07/04-06/05 Fellow in Interventional Cardiology, Massachusetts General Hospital, Boston, MA, Igor Palacios MD
07/05-06/07 Research Fellow in Cardiology, Cardiology, Massachusetts General Hospital, Boston, MA, Ken Bloch, MD
2002 ABIM Internal Medicine
2007/2015 ABIM Cardiovascular Disease
2008/2016 ABIM Interventional Cardiology
Dr. Finn is an interventional cardiologist and internationally recognized expert in the field of vascular biology and vascular device research. He currently serves as Medical Director and Chief of Research of CVPath and is head of the Institute’s basic and translational research laboratory. He is also an Associate Professor of Medicine at the University of Maryland, where he serves (part-time) as a cardiologist and interventional cardiologist.
He has published over 150 peer-reviewed research articles, editorials, and reviews. He is an editorial board member of Coronary Artery Disease and of Arteriosclerosis, Thrombosis, and Vascular Biology, and PLOS One.
His research interests are in the area of vascular biology, particularly human vascular disease. He has focused in particular on 1) the molecular mechanisms by which mTOR inhibitors delay endothelial recovery and function after vascular injury; 2) the role of alternative macrophage phenotypes in human atherosclerosis; 3) preclinical research in drug delivery as it relates to both drug-eluting stents and balloons; and 4) pathologic responses to structural heart devices.
He obtained his MD from Vanderbilt University in 2000. During medical school, he received a Howard Hughes Medical Student Research Fellowship and studied vascular gene therapy under David Dichek at the University of California at San Francisco. Dr. Finn did his internal medicine, cardiology and interventional cardiology training at the Massachusetts General Hospital in Boston, including two years of vascular biology research with Drs. Herman Gold and Rakesh Jain. Dr. Finn came to CVPath from Emory University in Atlanta where, from 2007 through 2015, he was Assistant Professor of Medicine and directed a basic and translational research laboratory.
Atherosclerosis, macrophages, drug-eluting stents, peripheral arterial disease, valvular heart disease
1. Akahori H, Karmali V, Polavarapu R, Lyle A, Weiss D, Shin E, Husain A, Naqvi N, Van Dam R, Habib A, Choi CU, King AL, Pachua K, Taylor WR, Lefer D, Finn AV. CD163 TWEAK Interaction Regulates Tissue Regeneration After Ischemic Injury. Nat Comm. 2015. Aug 5;6:7792. PMID:26242746.
2. Finn AV, Virmani R. The Clinical Challenge of Disappearing Stents. The Lancet. 2016 Feb 6;387:501-512. PMID: 26597772.
3. Mori H, Finn AV, Atkinson JB, Lutter C, Narula J, Virmani R. Calcified Nodule:
An Early and Late Cause of In-Stent Failure. JACC Cardiovasc Interv. 2016 Jun 6.
4. Mori H, Joner M, Finn AV, Virmani R. Malapposition: is it a major cause of
stent thrombosis? Eur Heart J. 2016 Apr 14;37(15):1217-9. PMID: 26802137.
5. Jaber WA, Finn AV. Intrastent Tissue Prolapse and Late Cardiac Events:
Innocent Bystander or Culprit? JACC Cardiovasc Interv. 2016 Jul 25;9(14):1508-9.
6. Koppara T, Sakakura K, Pacheco E, Cheng Q, Zhao X, Acampado E, Finn AV, Barakat M, Maillard L, Ren J, Deshpande M, Kolodgie FD, Joner M, Virmani R.
Preclinical evaluation of a novel polyphosphazene surface modified stent. Int J
Cardiol. 2016 Nov 1;222:217-25. doi: 10.1016/j.ijcard.2016.07.181. Epub 2016 Jul
7. PMID: 27497098.
7. Finn AV, Virmani R. Biodegradable polymer drug-eluting stents:
non-inferiority waiting for superiority? Lancet. 2016 Nov 26;388(10060):2567-2568. PMID: 27806901.
8. Lutter C, Mori H, Yahagi K, Ladich E, Joner M, Kutys R, Fowler D, Romero M, Narula J, Virmani R, Finn AV. Histopathological Differential Diagnosis of Optical
Coherence Tomographic Image Interpretation After Stenting. JACC Cardiovasc
Interv. 2016 Dec 26;9(24):2511-2523. PMID: 27889345.
9. Mori H, Kutys R, Romero M, Virmani R, Finn AV. Stenting of Spontaneous
Coronary Artery Dissection From a Pathological Point of View. Circ Cardiovasc
Interv. 2016 Dec;9(12). PMID: 27895071.
10. Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, Virmani R.
Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular
Calcification in Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2017
Feb;37(2):191-204. Review. PMID: 27908890; PubMed Central PMCID: PMC5269516.
11. Mori H, Lutter C, Yahagi K, Harari E, Kutys R, Fowler DR, Ladich E, Joner M,
Virmani R, Finn AV. Pathology of Chronic Total Occlusion in Bare-Metal Versus
Drug-Eluting Stents: Implications for Revascularization. JACC Cardiovasc Interv.
2017 Feb 27;10(4):367-378. PMID: 28161258.
12. Mori H, Harari E, Torii S, Virmani R, Finn AV. Evaluating the utility of
markers of thromboxane activity and oxidative stress in cardiovascular risk
prediction. Coron Artery Dis. 2017 Jun;28(4):275-277. PMID: 28225389.
13. Guo L, Harari E, Virmani R, Finn AV. Linking Hemorrhage, Angiogenesis,
Macrophages, and Iron Metabolism in Atherosclerotic Vascular Diseases.
Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):e33-e39. PMID: 28330947.
14. Mori H, Kutys R, Romero M, Virmani R, Finn AV. Metallic Coronary Stents: Is There a Relationship Between Stent Fracture and Hypersensitivity? JACC Cardiovasc Interv. 2017 Jun 12;10(11):1175-1177. PMID: 28527770.
15. Yahagi K, Ladich E, Kutys R, Mori H, Svensson LG, Mack MJ, Herrmann HC, Smith CR, Leon MB, Virmani R, Finn AV. Pathology of balloon-expandable transcatheter aortic valves. Catheter Cardiovasc Interv. 2017 Jun 1. PMID: 28569053.